gastric cancer

The European Commission has approved Deciphera Pharmaceuticals Inc's (NASDAQ: DCPH) Qinlock (ripretinib)for adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.  In...

AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSNKY) announced detailed results from the positive DESTINY-Gastric02 Phase 2 trial of Enhertu (fam-trastuzumab deruxtecan-nxki). The trial included HER2-positive metastatic and/or unresectable gastric or...

Leap Therapeutics Inc (NASDAQ: LPTX) announced updated data from the first-line cohort of the DisTinGuish Phase 2a trial evaluating DKN-01 combined with BeiGene Ltd’s (NASDAQ: BGNE) tislelizumab and chemotherapy in gastric or gastroesophageal junction cancer (G/GEJ...

Innovent Biologics Inc (OTC: IVBIY) has announced topline results from Phase 3 ORIENT-16 study evaluating sintilimab, meeting the primary endpoint of overall survival (OS). The trial assessed sintilimab in combination with chemotherapy (oxaliplatin and capecitabine) compared to...

The European Commission (EC) has approved Bristol Myers Squibb & Co's (NYSE: BMY) Opdivo (nivolumab) as adjuvant treatment of adult patients with esophageal or gastroesophageal junction (GEJ) cancer. The approval covers patients who have residual pathologic disease...

HUTCHMED (China) Limited (NASDAQ: HCM) and AstraZeneca Plc (NASDAQ: AZN) have initiated a Phase 2 study of Orpathys (savolitinib) in patients with advanced or metastatic MET amplified gastric cancer (GC) or adenocarcinoma of the gastroesophageal junction (GEJ). ...

On Thursday afternoon, Merck & Co Inc (NYSE: MRK) agreed to withdraw the U.S. accelerated approval indication for third-line gastric cancer indication for its blockbuster Keytruda (pembrolizumab) after late-stage confirmatory trials failed to show clinical benefit. The...

Five Prime Therapeutics Inc (Nasdaq: FPRX) revealed that the Food and Drug Administration (FDA) has granted Orphan Drug Designation to its FPA144 for gastric cancer treatment. That included cancer of the gastroesophageal junction in patients whose tumors over express FGFR2b. According to the...